Romison Rodrigues Mota – Director, ANVISA
Dr. Rodrigues Mota brings two decades of leadership experience within ANVISA, the Brazilian Health Regulatory Authority, where he has held multiple senior positions and now serves as a key architect…
Address: Setor de Indústria e Abastecimento (SIA) – Trecho 5, Área Especial 57, Brasília (DF) – CEP: 71205-050,Brazil
Tel: (61) 315-2005/315-2784
Web: http://portal.anvisa.gov.br/wps/portal/anvisa/home
ANVISA, the Brazilian equivalent of the FDA, promotes and protects the health of the population and evaluates risks involved in the production and use of products and services subject to sanitary surveillance in coordinated action with the states, municipalities and the Federal District, according to the principles of the Health System to improve the quality of life of the population.
Surveillance and health protection.
Dr. Rodrigues Mota brings two decades of leadership experience within ANVISA, the Brazilian Health Regulatory Authority, where he has held multiple senior positions and now serves as a key architect…
In an exclusive interview, Jarbas Barbosa da Silva, Director-President of the Brazilian Health Regulatory Agency (ANVISA), discusses some of the key specificities of the Brazilian market and highlights some of…
10 days ago, your Swedish counterpart Mats Larsson made a technical visit here at ANVISA and said he had a lot to learn. What is it about ANVISA that can…
The Brazilian pharma market outperformed the Latin American average in Q1 of 2020 with a growth of 8.2 percent in real terms (inflation adjusted), according to IQVIA. Its size reached…
Six of the top ten companies in the Brazilian pharma market are domestic.* Read on for an introduction to some of the Brazilian giants that are perhaps less well known…
Panorama Faramceutico’s editorial team look at how the ongoing COVID-19 pandemic stands to affect Brazil’s over the counter (OTC) market segment during and after the COVID-19 pandemic.* The OTC…
In the race to develop the world’s first COVID-19 vaccine, Brazil – now one of the world’s worst-affected countries – is becoming an attractive clinical trial destination for biopharma companies…
The editorial team at Panorama Farmaceutico explain how the COVID-19 pandemic and global trade flow stoppages are impacting the manufacture and supply of medicines within Brazil.* The COVID-19 pandemic…
The editorial team at Panorama Farmaceutico explain why coordinated action is needed within Brazilian pharma to reduce dependence on API imports from abroad and increase medical sovereignty. * The…
Below we highlight recent news in Brazilian pharma, including the impact of coronavirus as well as legal and regulatory updates. Proposal to allow breaking of patents due to Covid-19…
Swiss pharma giant Novartis is teaming up with the Oswaldo Cruz Foundation (Fiocruz) in Brazil to conduct research throughout Latin America on neglected diseases. This agreement establishes an exchange…
Three seasoned pharma executives with a wealth of experience working in Brazil offer their insights on leadership strategies for success in the massive, but complex, Brazilian pharma market. …
Rodrigo Araujo of global organizational consulting firm Korn Ferry outlines what he sees as the leadership profile of the future – agile, digital, self-aware, and able to transform both themselves…
When combining the sheer size of Brazil – the fifth largest country in the world – with its tropical climate, its largely perfectible infrastructure, and the soaring importance of temperature…
“Brazil undoubtedly holds great development opportunities for the global pharmaceutical and healthcare industries,” boldly states Minister of Health Ricardo Barros, “and we hope to gain the trust of an increasing…
See our Cookie Privacy Policy Here
